Vaccines comprising acapsular P. multocida hyaE deletion mutants
Inventors
Briggs, Robert E. • Tatum, Fred M.
Assignees
Biotechnology Research and Development Corp • US Department of Agriculture USDA
Publication Number
US-7351416-B2
Publication Date
2008-04-01
Expiration Date
2024-07-02
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Acapsular hyaE deletion mutants of P. multocida can be administered to mammals, particularly ungulates, or birds to provide protective immunity against wild-type P. multocida, e.g., to prevent or reduce the severity of hemorrhagic septicemia or pneumonia in mammals, particularly livestock, ungulates, and companion animals, or fowl cholera in birds, particularly poultry.
Core Innovation
The invention provides acapsular mutants of Pasteurella multocida serogroup A which comprise a deletion of all or part of the hyaE gene. This deletion results in attenuation of the bacterium and a corresponding loss of capsule production, creating an acapsular phenotype. Such mutants can be administered to mammals, including livestock, ungulates, companion animals, and birds, particularly poultry, to induce protective immunity against wild-type P. multocida.
The problem addressed by the invention is the need for effective vaccines that provide protective immunity against diseases caused by P. multocida, which is associated with various severe diseases such as hemorrhagic septicemia, pneumonia, and fowl cholera in different animal species. Existing vaccination strategies lacked effective acapsular mutants for this purpose.
The invention further encompasses vaccines comprising these acapsular hyaE deletion mutants in a pharmaceutically acceptable vehicle, feeds containing the mutants for administration to animals, and methods of inducing protective immunity through administration of the mutant bacteria by various routes. The mutants are preferably free of antibiotic resistance genes and exogenous DNA, enhancing environmental safety.
Claims Coverage
The patent contains multiple independent claims covering the acapsular P. multocida mutant bacterium, vaccines comprising the bacterium, feeds containing the bacterium, and methods of inducing protective immunity by administering the bacterium. The main inventive features focus on the specific hyaE gene deletion leading to the acapsular phenotype and the practical applications of the mutant bacteria.
Isolated P. multocida bacterium with hyaE gene deletion resulting in acapsular phenotype
An isolated P. multocida bacterium of serogroup A comprising a deletion in the coding region of the hyaE gene, where the deletion results in the bacterium acquiring an acapsular phenotype that attenuates the bacterium.
Vaccine comprising acapsular P. multocida mutant bacterium
A vaccine formulation for inducing protective immunity against wild-type P. multocida, containing the acapsular P. multocida mutant bacterium with a hyaE gene deletion and a pharmaceutically acceptable vehicle.
Feed suitable for ungulates or birds comprising acapsular mutant bacterium
Feeds suitable for ungulates or birds that include the acapsular P. multocida bacterium with the hyaE gene deletion to confer protective immunity when administered.
Method of inducing protective immunity by administering acapsular mutant bacterium
A method of inducing protective immunity against wild-type P. multocida by administering the acapsular P. multocida bacterium with the hyaE gene deletion to an ungulate or bird, thereby conferring protective immunity.
The patent claims cover the isolated P. multocida bacterium with hyaE deletion causing attenuation and acapsular phenotype, vaccines and feeds incorporating this bacterium, and methods for protective immunization of animals. The inventive focus lies in the specific genetic deletion and its applications for vaccination and animal health.
Stated Advantages
The mutant bacteria are attenuated, requiring a higher dose of wild-type bacteria to cause disease, indicating safety and reduced virulence.
The mutants confer protective immunity against P. multocida diseases such as hemorrhagic septicemia, pneumonia, and fowl cholera in various mammals and birds.
Mutants can be free of antibiotic resistance genes and exogenous DNA, improving environmental and ecological safety.
The mutants can be administered by various convenient routes, including oral administration via feed, enhancing ease of vaccination.
Documented Applications
Vaccination of mammals, particularly livestock, ungulates, and companion animals, for protection against hemorrhagic septicemia and pneumonia caused by wild-type P. multocida.
Vaccination of birds, particularly poultry, to prevent or reduce the severity of fowl cholera.
Administration of mutant bacteria via vaccines or feeds to induce protective immunity in target animals.
Interested in licensing this patent?